AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2015
Jun 3, 2015
30583_dirs_2015-06-03_4852af4c-bc06-4a7f-b2e8-0e48bcc3ecc0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2015-05-29
Reporting Person: SPIEGELMAN DANIEL K (EVP, Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2015-05-29 | Common Stock | F | 4305 | $125.57 | Disposed | 37202 | Direct |
| 2015-05-29 | Common Stock | S | 1578 | $126.1502 | Disposed | 35624 | Direct |
| 2015-06-01 | Common Stock | S | 3945 | $124.16 | Disposed | 31679 | Direct |
Footnotes
F1: This transaction, which should have been reported on June 2, 2015, is being reported late due to an administrative oversight.
F2: Trade made pursuant to a 10b5-1 plan executed on March 11, 2015.
F3: The price in column 4 is a weighted average price. The price actually received ranged from $125.60 to $127.78. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.
F4: The price in column 4 is a weighted average price. The price actually received ranged from $123.06.60 to $124.93. The reporting person shall provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price.